Spectrum Pharma Candidate Gets Positive Data - Analyst Blog
25 April 2014 - 7:50AM
Zacks
Spectrum Pharmaceuticals (SPPI) announced
encouraging results from a phase II pivotal study on
captisol-enabled melphalan. The candidate is being developed as an
intravenous formulation of melphalan (a well-known conditioning
therapy). Spectrum Pharma gained over 4% following the
announcement.
The candidate met the primary objective of the study of an overall
safety and toxicity profile before autologous stem cell
transplantation (ASCT) in patients suffering from multiple myeloma.
The study also evaluated the efficacy of captisol-enabled melphalan
in these patients as measured by the multiple myeloma response rate
(as per International Myeloma Working Group criteria) and the rates
of myeloablation and engraftment.
Spectrum Pharma is conducting additional analyses on the candidate.
The company intends to file a New Drug Application (NDA) for
captisol-enabled melphalan in the U.S. in the third quarter of this
year.
In Mar 2013, Spectrum Pharma acquired the development and
commercialization rights to captisol-enabled melphalan from
Ligand Pharmaceuticals Inc. (LGND). Ligand Pharma
will receive license fees, milestone payments and royalties from
Spectrum Pharma following potential commercialization of the
candidate.
Spectrum Pharma has Beleodaq (relapsed or refractory peripheral
T-cell lymphoma) under review in the U.S. A final decision from the
FDA on the approval of Beleodaq is expected by Aug 9, 2014. The
successful development and commercialization of both the candidates
will be beneficial for Spectrum Pharma.
Spectrum Pharma currently carries a Zacks Rank #3 (Hold). Some
better-ranked stocks include ImmunoGen, Inc.
(IMGN) and Biogen Idec Inc. (BIIB). While
ImmunoGen carries a Zacks Rank #1 (Strong Buy), Biogen holds a
Zacks Rank #2 (Buy).
BIOGEN IDEC INC (BIIB): Free Stock Analysis Report
IMMUNOGEN INC (IMGN): Free Stock Analysis Report
LIGAND PHARMA-B (LGND): Free Stock Analysis Report
SPECTRUM PHARMA (SPPI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024